The parade of investigations launched by government agencies into a big drugmaker is often shrugged off, at least by investors, who play wait-and-see since the outcome of such probes can, understandably, amount to nothing. However, the news that the US Department of Justice is investigating a key trial for the Brilinta bloodthinner sold by AstraZeneca may be a sobering reminder to pay close attention (see page 28).
Help employers find you! Check out all the jobs and post your resume.
